|
|
|
|
|
|
|
|
|
|
abstract
Highlights
- •
- Targeting HER2 has been extensively studied in ovarian and uterine carcinomas.
- •
- These cancers yielded negative trials—contrasting with breast and gastric cancers.
- •
- Future studies include HER2 resistance mechanisms and identifying predictive biomarkers.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.